CNS
Pharmanovia acquires CNS portfolio from Sanofi
September 20, 2023Medical Communications CNS, Neurology, Pharmanovia, Sanofi, acquisition
Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a selection of central nervous system …
Perception and Otsuka enter collaboration and licensing deal for depression drug candidate
March 16, 2021Manufacturing and Production CNS, Otsuka Pharmaceutical, Perception Neuroscience, depression
Perception Neuroscience and Otsuka Pharmaceutical have announced a collaboration and licensing agreement for the development and commercialisation of Perception’s lead …
Novartis’ Mayzent granted license by the European Medicines Agency
January 21, 2020Manufacturing and Production CNS, European Medicines Agency, NHS, NICE, Novartis
The European Medicines Agency (EMA) has granted a licence for the use of Mayzent (siponimod) in the treatment of certain …
Takeda opens R&D facility in San Diego, California
May 2, 2019Manufacturing and Production, Research and Development CNS, GI, Japan, Takeda, california, neuroscience, san diego
Japanese-firm Takeda pharmaceuticals has opened a new research facility in San Diego, California. The 165,000ft2 research centre will employ 250 …
CBD could be used to deliver drugs into the brain, research shows
April 18, 2019Research and Development BBB, CBD, CNS, brain, drug delivery, neuroscience
Cannabidiol (CBD), one of 113 cannabinoids in cannabis plants, could be used to deliver medicines into the brain, according to …
Biogen and Eisai discontinue Phase 3 Alzheimer’s trial
March 21, 2019Research and Development Alzheimer's, Biogen, CNS, Eisai, mental health
Biogen and Eisai have announced their decision to discontinue a Phase 3 trial looking into the efficacy and safety of …
Lundbeck and Otsuka’s bipolar treatment fails Phase 3 trials due to unexpected placebo effect
February 15, 2019Medical Communications CNS, Lundbeck, Otsuka, Rexulti, bipolar disorder, mental health
Lundbeck and Otsuka’s treatment for bipolar disorder, Rexulti, failed to achieve its primary endpoint in two separate Phase 3 trials. …
The new and improved Spring 2018 edition of Pharmafile is available to read online now!
May 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CNS, Cancer, Pharmafocus, cardiovascular, cvd, oncology, pharmafile
The Spring 2018 edition of Pharmafile, our long-running bi-annual guide to the latest trends, projections and thought leadership positions in …
Pfizer begins sell-off, shedding CNS drug to Biogen for $590m
March 13, 2018Manufacturing and Production, Sales and Marketing Biogen, CNS, Pfizer, biotech, drugs, pharma, pharmaceutical
Pfizer’s decision to back out of the neuroscience space was a strategic move that send shudders through the entire industry, …
Teva buys majority stake in genomic analysis firm
August 4, 2015Manufacturing and Production, Research and Development, Sales and Marketing CNS, Immuneering, Teva, central nervous system, genetic analysis
Teva has agreed to by a 51% equity share of genomic-analysis company Immuneering to advance treatments for diseases of the …
Teva bolsters neurology unit through Auspex deal
March 31, 2015Sales and Marketing CNS, SD-809, Teva, Tourette syndrome, auspex, deutetrabenazine, neurology
Teva is significantly enhancing its neurology business by acquiring US biopharma firm Auspex in a deal worth $3.5 billion. Teva …
Forest sold to Actavis for $25 billion
February 18, 2014Sales and Marketing Actavis, CNS, Forest, acquisition, labs, merger, synergy
The rumours of a substantial deal for Forest have been proven true after Actavis announced this afternoon that it will …
Allergan in $958m neurology deal
January 25, 2013Sales and Marketing Allergan, CNS, MAP Pharmaceuticals, migraine
Allergan is to pay $958m for MAP Pharmaceuticals in a deal which sees both companies hoping to reap the benefits …
Takeda to buy Envoy Therapeutics
November 7, 2012Research and Development, Sales and Marketing CNS, Envoy, Parkinson's, Parkinsons, Takeda
Takeda Pharmaceutical Company has bought another private US firm, its second in as many months. The Japanese group is paying …
UK at centre of Eisai plans
September 18, 2012Research and Development, Sales and Marketing CNS, Cancer Drugs Fund, Eisai, Fycompa, Halaven
Diseases of the central nervous system (CNS) and cancer will be the main areas targeted by Japanese firm Eisai as …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
